These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 33849918)

  • 1. Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs.
    van Ouwerkerk L; van der Meulen-de Jong AE; Ninaber MK; Teng YKO; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2021 Oct; 80(10):1364-1365. PubMed ID: 33849918
    [No Abstract]   [Full Text] [Related]  

  • 2. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
    Spiera R; Jinich S; Jannat-Khah D
    Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 Reinfection in An Immunosuppressed Patient Without An Antibody Response.
    Hunsinger DHP; Kutti Sridharan DG; Rokkam DVRP; Fantry DLE
    Am J Med Sci; 2021 Jul; 362(1):103. PubMed ID: 33612185
    [No Abstract]   [Full Text] [Related]  

  • 5. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

  • 6. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
    Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
    Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
    Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
    Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study.
    Sarzi-Puttini P; Marotto D; Caporali R; Montecucco CM; Favalli EG; Franceschini F; Fredi M; Balduzzi S; Bazzani C; Bongiovanni S; Giorgi V; Batticciotto A; Cappelli A; Balzarini P; Dagna L; Sartorelli S; Ravagnani V; Tamanini S; Farah S; Faggioli P; Castelnovo L; Lurati AM; Galli M; Salaffi F
    J Autoimmun; 2021 Jan; 116():102545. PubMed ID: 32972804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
    Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
    mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Albach FN; Burmester GR; Biesen R
    Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
    [No Abstract]   [Full Text] [Related]  

  • 11. The COVID-19 Pandemic Rages on for People Who Are Immunocompromised.
    Rubin R
    JAMA; 2022 May; 327(19):1853-1855. PubMed ID: 35476006
    [No Abstract]   [Full Text] [Related]  

  • 12. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.
    Živković SA; Gruener G; Narayanaswami P;
    Muscle Nerve; 2021 Mar; 63(3):294-303. PubMed ID: 33471383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immunosuppressive drugs in immune-mediated inflammatory disease during the coronavirus pandemic.
    Giuliani F; Gualdi G; Amerio P
    Dermatol Ther; 2020 Nov; 33(6):e14204. PubMed ID: 32829511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of COVID-19 on Pediatric Immunocompromised Patients.
    Connelly JA; Chong H; Esbenshade AJ; Frame D; Failing C; Secord E; Walkovich K
    Pediatr Clin North Am; 2021 Oct; 68(5):1029-1054. PubMed ID: 34538297
    [No Abstract]   [Full Text] [Related]  

  • 15. [A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic].
    Schmeiser T; Broll M; Dormann A; Fräbel C; Hermann W; Hudowenz O; Keil F; Müller-Ladner U; Özden F; Pfeiffer U; Saech J; Schwarting A; Stapfer G; Steinchen N; Storck-Müller K; Strunk J; Thiele A; Triantafyllias K; Wassenberg S; Wilden E; Hasseli R
    Z Rheumatol; 2020 May; 79(4):379-384. PubMed ID: 32303821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-edged sword of using opioids and COVID-19: a toxicological view.
    Ataei M; Shirazi FM; Lamarine RJ; Nakhaee S; Mehrpour O
    Subst Abuse Treat Prev Policy; 2020 Dec; 15(1):91. PubMed ID: 33272308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center.
    Freeman MC; Rapsinski GJ; Zilla ML; Wheeler SE
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):426-431. PubMed ID: 33049042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 Infection in an Immunosuppressed Patient with Arthritis.
    Braun-Moscovici Y; Zisman D; Balbir-Gurman A
    Isr Med Assoc J; 2020 Aug; 22(8):523-524. PubMed ID: 33236589
    [No Abstract]   [Full Text] [Related]  

  • 20. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future.
    Winthrop KL; Whitley RJ; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.